Sign In
Buy CARA
$5.32
+0 (+0%)
At Close: Jul 14, 2025
DocuSign To Rally Around 25%? Here Are 10 Other Analyst Forecasts For Tuesday
12:39pm, Tuesday, 07'th Mar 2023 Benzinga
Wells Fargo cut the price target for Cheniere Energy, Inc. (NYSE: LNG) from $236 to $230. Wells Fargo analyst Michael Blum maintained an Overweight rating. Cheniere Energy shares fell 4.8% to close
Cara Therapeutics Gets Price Targets Cuts By Analysts After Weak Q4 Results
12:18pm, Tuesday, 07'th Mar 2023 Benzinga
Cara Therapeutics, Inc. (NASDAQ: CARA) posted downbeat Q4 results.
Cara Therapeutics posted a Q4 loss of $0.56 per share, versus market expectations of $0.32 per share. The company’s quarterly sales
Nutanix, Cara Therapeutics, Tremor International And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
11:11am, Tuesday, 07'th Mar 2023 Benzinga
U.S. stock futures traded higher this morning. Here are some big stocks recording losses in today’s pre-market trading session.
Cara Therapeutics, Inc. (NASDAQ: CARA) shares dropped 30.6% to $6.94
Cara Therapeutics stock sinks on larger-than-expected Q4 earnings miss
10:13am, Tuesday, 07'th Mar 2023
Yahoo Finance Live anchors Julie Hyman and Jared Blikre discuss fourth-quarter earnings for Cara Therapeutics.
These 2 Stocks Are Plunging After Hours Monday
12:39am, Tuesday, 07'th Mar 2023 The Motley Fool
The market closed mixed, but these two companies gave investors some bad news.
Cara Therapeutics (CARA) Reports Q4 Loss, Misses Revenue Estimates
10:15pm, Monday, 06'th Mar 2023 Zacks Investment Research
Cara (CARA) delivered earnings and revenue surprises of -69.70% and 76.75%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Cara Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results
09:01pm, Monday, 06'th Mar 2023 GlobeNewswire Inc.
– 4Q22 total revenue was $3.3 million including collaborative revenue of $1.1 million from the Company’s share of profit of KORSUVA® (difelikefalin) injection; FY22 revenue was $41.9 million incl
Cara Therapeutics, Inc. (CARA) Q4 2022 Earnings Call Transcript
08:44pm, Monday, 06'th Mar 2023
Cara Therapeutics, Inc. (NASDAQ:CARA ) Q4 2022 Results Conference Call March 6, 2023 4:30 PM ET Company Participants Matt Murphy - Manager, IR Chris Posner - CEO Ryan Maynard - CFO Dr. Joana Goncalves
These 2 Stocks Are Plunging After Hours Monday
07:39pm, Monday, 06'th Mar 2023
Markets finished mixed on Monday. Calavo suffered from the downward price impact of supply gluts of avocados from Mexico.
Cara Therapeutics (CARA) Reports Q4 Loss, Misses Revenue Estimates
06:49pm, Monday, 06'th Mar 2023
Cara (CARA) delivered earnings and revenue surprises of -69.70% and 76.75%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Will Cara Therapeutics (CARA) Report Negative Earnings Next Week? What You Should Know
03:00pm, Monday, 27'th Feb 2023 Zacks Investment Research
Cara (CARA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cara Therapeutics to Announce Fourth Quarter and Full Year 2022 Financial Results on March 6, 2023
07:00am, Tuesday, 21'st Feb 2023
STAMFORD, Conn., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patien
Cara Therapeutics Announces Results from the KOMFORT Phase 2 Trial of Oral Difelikefalin for the Treatment of Pruritus in Notalgia Paresthetica Published in the New England Journal of Medicine
10:00pm, Wednesday, 08'th Feb 2023 GlobeNewswire Inc.
Publication underscores the importance of data in underrecognized neuropathic itch disorder which lacks an approved treatment Publication underscores the importance of data in underrecognized neuropat
7 Steps to Investing in Marijuana Stocks
06:49pm, Friday, 16'th Dec 2022 The Motley Fool
Here are seven steps to investing in the high-flying cannabis industry.
Cara Therapeutics (CARA) Reports Q3 Loss, Tops Revenue Estimates
10:35pm, Monday, 07'th Nov 2022 Zacks Investment Research
Cara (CARA) delivered earnings and revenue surprises of -2.38% and 28.91%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
